Structure Therapeutics (GPCR) Net Income towards Common Stockholders (2022 - 2026)

Structure Therapeutics' Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$76.0 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 62.21% year-over-year to -$76.0 million in Q1 2026; TTM through Mar 2026 was -$25.6 million, a 15.47% increase from a year earlier, with the FY2025 full-year figure at $3.6 million, up 137.9% from the prior year.
• Net Income towards Common Stockholders fell to -$76.0 million in Q1 2026 per GPCR's latest filing, from $177.8 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $177.8 million in Q4 2025 and bottomed at -$76.0 million in Q1 2026.
• The 5-year median for Net Income towards Common Stockholders is -$23.3 million (2023), against an average of -$5.9 million.
• Biggest YoY gain for Net Income towards Common Stockholders was 132.06% in 2025; the steepest drop was 136.85% in 2025.
• Year by year, Net Income towards Common Stockholders stood at $32.3 million in 2022, then jumped by 72.31% to $55.7 million in 2023, then jumped by 37.55% to $76.6 million in 2024, then jumped by 132.06% to $177.8 million in 2025, then sank by 142.73% to -$76.0 million in 2026.
• Per Business Quant, the three latest GPCR Net Income towards Common Stockholders figures stand at -$76.0 million (Q1 2026), $177.8 million (Q4 2025), and -$65.7 million (Q3 2025).